ストックスクリーナーアプリを入手
0.1989
5.47%
-0.0115
アフターアワーズ：
.19
-0.0089
-4.47%
前日終値:
$0.2104
開ける：
$0.2
24時間の取引高:
1.44M
Relative Volume:
0.97
時価総額：
$16.73M
収益：
-
当期純損益:
$-26.92M
株価収益率:
-0.39
EPS:
-0.51
ネットキャッシュフロー:
$-18.92M
1週間 パフォーマンス:
-16.74%
1か月 パフォーマンス:
-38.04%
6か月 パフォーマンス:
-81.75%
1年 パフォーマンス:
-89.25%
1日の値動き範囲:
$0.1814
$0.2056
1週間の範囲:
$0.1814
$0.2463
52週間の値動き範囲:
$0.1814
$2.39
Cel-Sci Corp. Stock (CVM) Company Profile
名前
Cel-Sci Corp.
セクター
電話
703-506-9460
住所
8229 Boone Boulevard, Suite 802, Vienna, VA
CVM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
0.1989 | 16.73M | 0 | -26.92M | -18.92M | -0.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-01-13 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-02 | 開始されました | Dawson James | Buy |
Cel-Sci Corp. (CVM) 最新ニュース
CVM stock touches 52-week low at $0.23 amid sharp annual decline By Investing.com - Investing.com South Africa
CVM stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com Australia
CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World
Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients - Stock Titan
CVM stock touches 52-week low at $0.26 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.26 amid sharp annual decline By Investing.com - Investing.com South Africa
Cel-Sci Corp (CVM) Volatility Hits 12.01%: What Good Investors Need To Be Aware Of - Stocks Register
CEL-SCI announces closing of $2.5 million offering -March 18, 2025 at 05:23 pm EDT - Marketscreener.com
CEL-SCI Secures $2.5M Funding: Major Push for FDA-Designated Cancer Immunotherapy - StockTitan
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga
CEL-SCI Secures Critical Funding for FDA-Approved Head & Neck Cancer Treatment Study - StockTitan
CEL-SCI advances in head and neck cancer treatment study - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
CEL-SCI advances in head and neck cancer treatment study By Investing.com - Investing.com UK
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine - Yahoo Finance
Cel-Sci Corp (CVM) Recovers 5.85% From Low: Are We There Yet? - Stocks Register
Major Breakthrough: JAMA Study Shows Multikine Triples Survival Rates in Head and Neck Cancer - StockTitan
CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com - Defense World
CVM stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa
4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal
CEL-SCI Announces That NYSE MKT Granted an Extension to Regain Compliance - AOL
CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline - Investing.com Australia
CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline By Investing.com - Investing.com South Africa
CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Armenian Reporter
CEL-SCI advances Multikine study for head and neck cancer - Investing.com
CEL-SCI advances Multikine study for head and neck cancer By Investing.com - Investing.com UK
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial -February 20, 2025 at 08:06 am EST - Marketscreener.com
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial - Yahoo Finance
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - BioSpace
StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Armenian Reporter
Breakthrough Cancer Treatment Shows 73% Survival Rate: CEL-SCI's Latest Clinical Milestone - Stock Titan
CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com - Defense World
Cel-Sci: Fiscal Q1 Earnings Snapshot - mySA
Cel-Sci: Fiscal Q1 Earnings Snapshot -February 14, 2025 at 04:25 pm EST - Marketscreener.com
CVM: Fiscal Year 2024 Results - Research Tree
LD Micro 360 Companies Set to Present this Week - ACCESS Newswire
Personal Finance - Business Wire
Short Interest in DoubleLine Income Solutions Fund (NYSE:DSL) Increases By 8.7% - Defense World
Have A Relaxing Holiday Season - MENAFN.COM
Cantex Mine Development (CVE:CD) Stock Price Up 9.5% – Should You Buy? - Defense World
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer - Yahoo Finance
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
CVM stock touches 52-week low at $0.37 amid sharp annual decline - Investing.com Nigeria
Cel-Sci Corp. (CVM) 財務データ
収益
当期純利益
現金流量
EPS
1.23%
1.63%
大文字化:
|
ボリューム (24 時間):